Longitudinal association between medication adherence and lung health in people with cystic fibrosis
Longitudinal association between medication adherence and lung health in people with cystic fibrosis
复制标题
DOI：
10.1016/j.jcf.2011.03.005
复制
发表时间：
2011-07-01
影响因子：
5.2
通讯作者：
Riekert, Kristin A.
中科院分区：
文献类型：
--
作者：
Eakin, Michelle N.;Bilderback, Andrew;Riekert, Kristin A.
背景资料：本研究探讨了药物依从性与肺恶化频率和FEV1%预测值（FEV 1）下降率的关系。方法：95例6岁或以上的CF患者，并开具肺部药物，入选了一项纵向回顾性研究，研究药物依从性和健康结局（静脉（IV）抗生素治疗和FEV 1的发生率和频率）超过12个月。结果：在控制了性别、基线FEV 1和治疗方案复杂性后，复合MPR预测至少一次需要IV抗生素治疗的肺部急性加重的发生（IRR=2.34，p=0.05），但不能预测急性加重的频率。复合MPR可预测基线FEV 1（估计值=29.81，p=.007），但不能预测FEV 1的下降。结论：这些结果表明CF患者的药物依从性与IV抗生素之间存在显著关系，强调了在门诊访视期间解决依从性以改善健康结果的重要性。(C)2011年欧洲囊性纤维化协会。Elsevier B. V.出版，保留所有权利。
Background: This study examined the relationship of medication adherence to frequency of pulmonary exacerbation and rate of decline in FEV1 % predicted (FEV1).Methods: 95 CF patients aged 6 years or older and prescribed a pulmonary medication, were enrolled in a longitudinal retrospective review of medication adherence and health outcomes (the occurrence and frequency of intravenous (IV) antibiotic treatments and FEV1) over 12-months. Pharmacy refill records were used to calculate a medication possession ratio (MPR).Results: Composite MPR predicted the occurrence of at least one pulmonary exacerbation requiring a course of IV antibiotics (IRR=2.34, p=0.05), but not the frequency of exacerbations, after controlling for gender, baseline FEV1, and regimen complexity. Composite MPR predicted baseline FEV1 (estimate=29.81, p=.007), but not decline in FEV1.Conclusions: These results demonstrate a significant relation between medication adherence and IV antibiotics in CF patients, highlighting the importance of addressing adherence during clinic visits to improve health outcomes. (C) 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.